BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Enrupatinib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Enrupatinib\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07903337-725@assetmemo.bio
DTSTAMP:20261121T005730Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Enrupatinib: Phase 1 readout est. (NCT07903337)
DESCRIPTION:Enrupatinib\, phase 1.\nStudy: A Phase 1\, Open-Label\, Two-Sta
 ge\, Food Effect Study to Assess the Safety\, Tolerability\, and Pharmacok
 inetics of EI-1071 Under Fasted or Fed Conditions in Healthy Volunteers\nE
 stimated primary completion: August 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/enrupatinib#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07903337
URL:https://assetmemo.bio/drug/enrupatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
